These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25333750)

  • 1. Imaging cellular distribution of Bcl inhibitors using small molecule drug conjugates.
    Giedt RJ; Sprachman MM; Yang KS; Weissleder R
    Bioconjug Chem; 2014 Nov; 25(11):2081-5. PubMed ID: 25333750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1.
    Guo Z; Song T; Xue Z; Liu P; Zhang M; Zhang X; Zhang Z
    Eur J Pharm Sci; 2020 Jan; 142():105105. PubMed ID: 31669390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
    Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
    J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3 mimetics: status of the field and new developments.
    Billard C
    Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA.
    Muenchow A; Weller S; Hinterleitner C; Malenke E; Bugl S; Wirths S; Müller MR; Schulze-Osthoff K; Aulitzky WE; Kopp HG; Essmann F
    Cell Death Dis; 2020 Aug; 11(8):701. PubMed ID: 32839432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
    Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
    Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.
    Li X; Dou J; You Q; Jiang Z
    Eur J Med Chem; 2021 Aug; 220():113539. PubMed ID: 34034128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell- and Tissue-Based Proteome Profiling and Dual Imaging of Apoptosis Markers with Probes Derived from Venetoclax and Idasanutlin.
    Zhu D; Guo H; Chang Y; Ni Y; Li L; Zhang ZM; Hao P; Xu Y; Ding K; Li Z
    Angew Chem Int Ed Engl; 2018 Jul; 57(30):9284-9289. PubMed ID: 29768700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-2: Long and winding path from discovery to therapeutic target.
    Schenk RL; Strasser A; Dewson G
    Biochem Biophys Res Commun; 2017 Jan; 482(3):459-469. PubMed ID: 28212732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca
    Jakubowska MA; Kerkhofs M; Martines C; Efremov DG; Gerasimenko JV; Gerasimenko OV; Petersen OH; Bultynck G; Vervliet T; Ferdek PE
    Br J Pharmacol; 2019 Nov; 176(22):4402-4415. PubMed ID: 30266036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma.
    Wang Y; Wang Y; Fan X; Song J; Wu H; Han J; Lu L; Weng X; Nie G
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1214-1220. PubMed ID: 30017199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
    Vandenberg CJ; Cory S
    Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.
    Deng J; Letai A
    Breast Cancer Res; 2013; 15(5):317. PubMed ID: 24172207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
    Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC
    Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.
    Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M
    PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically relevant interactions of anti-apoptotic Bcl-2 protein inhibitors with ABC transporters.
    Ruzickova E; Janska R; Dolezel P; Mlejnek P
    Pharmazie; 2017 Dec; 72(12):751-758. PubMed ID: 29441961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.